Phase I Study, Open, Dose Escalation, in Adult Patients With Advanced Solid Tumours, to Evaluate Tolerability, Pharmacokinetics and Pharmacodynamics of PDM08 Administered Twice a Week Cycles of 4 Weeks.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2015
At a glance
- Drugs PDM 08 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Laboratoires Prodimed
- 10 Jun 2017 Biomarkers information updated
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2012 Planned number of patients changed from 38 to 23 as reported by ClinicalTrials.gov.